Last reviewed · How we verify

Remifentanil 2 µg/kg

Rigshospitalet, Denmark · FDA-approved active Small molecule

Remifentanil is a potent synthetic opioid agonist that binds to mu (μ) opioid receptors in the central nervous system to produce rapid analgesia and sedation.

Remifentanil is a potent synthetic opioid agonist that binds to mu (μ) opioid receptors in the central nervous system to produce rapid analgesia and sedation. Used for Intraoperative analgesia during general anesthesia, Sedation and analgesia in mechanically ventilated patients in intensive care settings.

At a glance

Generic nameRemifentanil 2 µg/kg
SponsorRigshospitalet, Denmark
Drug classOpioid agonist
TargetMu (μ) opioid receptor
ModalitySmall molecule
Therapeutic areaAnesthesia and Analgesia
PhaseFDA-approved

Mechanism of action

Remifentanil activates mu opioid receptors, which inhibit pain signal transmission and modulate consciousness. It is an ester-based opioid that is rapidly metabolized by non-specific plasma and tissue esterases, resulting in a very short half-life (approximately 10–20 minutes) and rapid offset of action, making it suitable for intraoperative and short-procedure analgesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: